PGNY vs RMD: fair value comparison
Progyny, Inc. and ResMed Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, PGNY currently sits closer to the top of our discount ranking.
| PGNY | RMD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $25.66 | $218.27 |
| 12-month range | $16.86–$31.53 | $186.44–$257.39 |
| Sector rank | #21 of 113 Healthcare | #25 of 113 Healthcare |
| Quality grade | A | A |
| Momentum grade | — | B |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: PGNY fair value analysis · RMD fair value analysis